[{"orgOrder":0,"company":"Zucero Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Pixatimod","moa":"SARS-CoV-2 S1","graph1":"Oncology","graph2":"Phase I","graph3":"Zucero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zucero Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zucero Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Zucero Therapeutics","sponsor":"Statistical Revelations Pty Ltd | Datapharm Australia","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Pixatimod","moa":"SARS-CoV-2 S1","graph1":"Oncology","graph2":"Phase I","graph3":"Zucero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Zucero Therapeutics \/ Statistical Revelations Pty Ltd | Datapharm Australia","highestDevelopmentStatusID":"6","companyTruncated":"Zucero Therapeutics \/ Statistical Revelations Pty Ltd | Datapharm Australia"},{"orgOrder":0,"company":"Zucero Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pixatimod","moa":"SARS-CoV-2 S1","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Zucero Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zucero Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Zucero Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Diwakar Davar","sponsor":"Aculeus Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Pixatimod","moa":"SARS-CoV-2 S1","graph1":"Oncology","graph2":"Phase II","graph3":"Diwakar Davar","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Diwakar Davar \/ Aculeus Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Diwakar Davar \/ Aculeus Therapeutics"}]